Elsevier

Placenta

Volume 52, April 2017, Pages 62-70
Placenta

Altered placental tryptophan metabolic pathway in human fetal growth restriction

https://doi.org/10.1016/j.placenta.2017.02.013Get rights and content

Highlights

  • The human placenta activity converts tryptophan to kynurenine metabolites from early (1st trimester) pregnancy.

  • Enzymes responsible for kynurenine production are significantly lower in placentas from FGR compared with control.

  • Synthesis and release of kynurenine metabolites in placental explants was lower under 5% O2 compared to 20% O2.

  • Activity of kynurenine pathways enzymes are sensitive to oxygen and conditions that produce FGR.

Abstract

Introduction

Tryptophan is a substrate for kynurenine pathway metabolism in the placenta. We investigated if kynurenine metabolites change over gestation, if they are different between pregnancies with normal and fetal growth restriction (FGR), and if the oxygen environment modulated kynurenine pathway activity in the human placenta.

Methods

Tryptophan, kynurenine, and downstream kynurenine metabolites were determined in maternal venous blood, umbilical cord blood, and placental samples obtained in 1st and 3rd trimester pregnancies including FGR, and in the media of placental explants incubated with 20% or 5–8% O2 for 24, 48 or 72 h.

Results

All the major kynurenine metabolites were present in cord blood, and in general were higher than in maternal blood. IDO and TDO mRNA and protein expression, responsible for kynurenine production from tryptophan, were significantly lower in placentas from FGR pregnancies compared with control. Explants prepared from 1st and 3rd trimester placentas actively produced all the major kynurenine pathway metabolites which, together with expression of IDO, TDO, KYN-OHase and 3HAO mRNAs, were significantly lower after 24 h exposure to 5–8% O2 compared to 20% O2

Conclusions

Expression and activity of the kynurenine pathway is present in the placenta from early gestation, and is down-regulated by hypoxia and in FGR pregnancies.

Introduction

During pregnancy the essential amino acid tryptophan is actively transported to the fetus by the placenta [1]. Besides being utilised for protein synthesis by the placenta and fetus, another fate of tryptophan is degradation via the serotonin and kynurenine pathways. Tryptophan hydroxylase-1 is known to be highly expressed in the placenta of several species [2], and in mice placental synthesis of serotonin is important for early brain development [3]. Serotonin may also be important for maintaining vasodilation of the uterine circulation in the vicinity of the implanted placenta [4]. Tryptophan is also oxidised by enzymes tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), both of which are expressed in the human placenta (2). In early murine pregnancy IDO activity has been implicated in suppression of the maternal immune response to the conceptus [5], [6]. The role of this pathway in human pregnancy during early and late gestation is unclear.

Kynurenine produced as a result of either IDO or TDO activity is further degraded by vitamin B2- and B6-dependent enzymes to kynurenic acid (KA), anthranilic acid (AA), 3-hydroxykynurenine (HK), xanthurenic acid (XA) and 3-hydroxyanthranilic acid (HAA) (2, 6). IDO expression is induced by several inflammatory mediators, including interferon-γ (5, 7), resulting in decreased blood concentrations of tryptophan and increased blood concentrations of kynurenine and kynurenine pathway metabolites (5, 7). This is relevant to pregnancy because many kynurenine metabolites have actions within the central nervous system, and might impact on the fetal brain. For example, kynurenine is a convulsant [7], whereas kynurenic acid, a NMDA receptor antagonist, has anti-convulsant properties [8]. Quinolinic acid, a NMDA receptor agonist and an excitotoxin, has been implicated in many neurological disorders such as Alzheimer's and Huntington's disease [9], [10]. In addition, 3-hydroxykunurenine, anthranilic acid and 3-hydroxyanthranilic acid have cytotoxic properties [11], and picolinic acid is both a chemo-attractant for macrophages and can potentiate free radical damage [12], [13].

It has been proposed that placenta-derived kynurenine metabolites may be involved in the aetiology of perinatal brain damage (2). The human placenta expresses mRNAs of many kynurenine pathway enzymes throughout pregnancy, including both IDO and TDO [14], [15]. Placental explants produce tryptophan metabolites, including kynurenine, kynurenic acid, 3-hydroxyanthranilic acid, picolinic acid and quinolinic acid; all of these kynurenine pathway metabolites are also present in umbilical cord blood at term [15], [16]. Placental expression of several kynurenine pathway enzymes is increased in response to maternal infection, and placental kynurenine and quinolinic acid production increase with exposure to inflammation provoked by infection [15], confirming that activity of the kynurenine pathway in the placenta is very sensitive to infection and inflammation.

Little is known about circulating levels of tryptophan metabolites throughout normal physiological events such as pregnancy and labour, or of the ability of the placenta to produce kynurenines during stress, such as the hypoxia that often arises n late gestation and at parturition. Also, fetal growth restriction (FGR), which affects 5–15% of pregnancies in first world countries and up to 55% in developing countries, is a significant pregnancy disorder that has major consequences for the fetus and neonate such as higher rates of perinatal mortality, hypoxic ischemic encephalopathy, cerebral palsy, and a long-term morbidity extending into adulthood. Impaired placental function such as reduced activity of placental nutrient transporters contributes to the etiology of FGR [17], [18], but the involvement of altered tryptophan catabolism as a condition associated with human FGR is unclear.

Given that IDO gene expression is increased by inflammatory mediators [1], [2], [15], we hypothesized that activity of the tryptophan-kynurenine pathway would increase across gestation. Furthermore, because IDO is an oxygen-dependent enzyme and FGR is associated with fetal hypoxia, we hypothesized that kynurenine and the downstream metabolites would be decreased in pregnancies where FGR develops in late pregnancy. To examine these hypotheses we collected maternal and cord venous bloods from women undergoing delivery by either spontaneous or elective caesarean delivery at term. Furthermore, we collected placentas from women delivering at term, and compared these with samples collected at 1st trimester from elective termination of pregnancy. Finally, placental samples were also available to us from idiopathic FGR-affected and gestation age-matched pregnancies, allowing us to determine the effect of constitutive growth restriction on the expression of key kynurenine pathway enzymes in these placentas. Our results show that the tryptophan-kynurenine pathway is active in the placenta from early pregnancy, and that activity of the kynurenine enzymes are sensitive to condition that produce feto-placental growth restriction.

Section snippets

Materials and methods

Approval for this project was granted by the Monash Medical Centre Human Research and Ethics committee and from the Royal Women's Hospital Human and Research Ethics Committees, Melbourne with written consent given by all patients.

Maternal and umbilical cord blood

Arterial and venous cord blood was collected at the time of delivery from pregnancies of 37–41 weeks after spontaneous vaginal delivery (SVD, n = 10) or and caesarean section (C/S, n = 11). Blood samples were centrifuged at 3000 g and the plasma collected and stored at −20 °C until analysis.

Kynurenine pathway metabolites in cord blood

Tryptophan and all kynurenine metabolites were detectable in all maternal and cord arterial and venous bloods at term (Table 3). There were no consistent differences between arterial and venous cord samples for either mode of delivery, except for picolinic acid which was 3.9-fold higher in umbilical artery (4.3 μM) compared to vein samples (1.1 μM) after spontaneous vaginal delivery. Vaginal delivery was associated with higher kynurenine and 3-hydoxyanthranilic acid in arterial and venous cord

Discussion

This study shows that both the mRNAs and proteins of IDO and TDO are expressed in the human placenta from early gestation. Although these results cannot be taken as indicative of enzyme activity (the samples available to us were not suitable for this purpose), they do confirm that the genes products are translated through to cellular protein.

IDO is induced by pro-inflammatory signals, in particular by IFN-gamma, which may be involved in the local depletion of tryptophan, thereby suppressing of

Conclusion

Our study demonstrates that temporal expression of the key enzymes IDO and TDO may contribute to the pathogenesis of human FGR. Furthermore, early expression and activity of tryptophan metabolites, specifically the kynurenine metabolites in response to change in oxygen tension highlights their importance to feto-placental growth in human FGR.

Conflict of interest

Authors have no conflict of interests to declare.

Acknowledgements

The authors would like to thank Dr Ursula Manuelpillai and Dr Poonam Dharane from the Department of Obstetrics and Gynaecology, Monash University for their technical help. Monash Health is supported by the Victorian Government's Operational Infrastructure Support Program. The authors would like to thank the women who consented to provide samples to the study. The following are gratefully acknowledged: the clinical Research Midwives for sample collection and the Obstetrics and Midwifery staff of

References (46)

  • A.A. Badawy

    Tryptophan metabolism, disposition and utilization in pregnancy

    Biosci. Rep.

    (2015)
  • P. Sedlmayr et al.

    The role of placental tryptophan catabolism

    Front. Immunol.

    (2014)
  • A. Bonnin et al.

    Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain

    Neuroscience

    (2011)
  • G. Haugen et al.

    Vasoactive effects of intra- and extravascular serotonin, PGE2 and PGF2 alpha in human umbilical arteries

    Gynecol. Obstet. Invest.

    (1991)
  • A.L. Mellor et al.

    Tryptophan catabolism prevents maternal T cells from activating lethal anti-fetal immune responses

    J. Reprod. Immunol.

    (2001)
  • A.L. Mellor et al.

    Extinguishing maternal immune responses during pregnancy: implications for immunosuppression

    Semin. Immunol.

    (2001)
  • I.P. Lapin

    Kynurenines and seizures

    Epilepsia

    (1981)
  • A.A. Fatokun et al.

    Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons

    Brain Res.

    (2008)
  • I.D. Maksimovic et al.

    Oxidative damage and metabolic dysfunction in experimental Huntington's disease: selective vulnerability of the striatum and hippocampus

    Vojnosanit. Pregl.

    (2001)
  • G.J. Guillemin et al.

    Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus

    Neuropathol. Appl. Neurobiol.

    (2005)
  • A. Chiarugi et al.

    Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase

    J. Neurochem.

    (1996)
  • L. Varesio et al.

    Picolinic acid, a catabolite of tryptophan, as the second signal in the activation of IFN-gamma-primed macrophages

    J. Immunol.

    (1990)
  • M.C. Bosco et al.

    Macrophage activating properties of the tryptophan catabolite picolinic acid

    Adv. Exp. Med. Biol.

    (2003)
  • U. Manuelpillai et al.

    Increased mRNA expression of kynurenine pathway enzymes in human placentas exposed to bacterial endotoxin

    Adv. Exp. Med. Biol.

    (2003)
  • U. Manuelpillai et al.

    Identification of kynurenine pathway enzyme mRNAs and metabolites in human placenta: up-regulation by inflammatory stimuli and with clinical infection

    Am. J. Obstet. Gynecol.

    (2005)
  • P. Ligam et al.

    Localisation of indoleamine 2,3-dioxygenase and kynurenine hydroxylase in the human placenta and decidua: implications for role of the kynurenine pathway in pregnancy

    Placenta

    (2005)
  • T. Jansson et al.

    The role of trophoblast nutrient and ion transporters in the development of pregnancy complications and adult disease

    Curr. Vasc. Pharmacol.

    (2009)
  • E. Shibata et al.

    Placental system A amino acid transport is reduced in pregnancies with small for gestational age (SGA) infants but not in preeclampsia with SGA infants

    Placenta

    (2008)
  • R.L. Guaran et al.

    Update of growth percentiles for infants born in an Australian population

    Aust. N. Z. J. Obstet. Gynaecol.

    (1994)
  • U. Manuelpillai et al.

    Effect of hypoxia on placental activin A, inhibin A and follistatin synthesis

    Placenta

    (2003)
  • H. Kazda et al.

    Maternal, umbilical, and amniotic fluid concentrations of tryptophan and kynurenine after labor or cesarean section

    Pediatr. Res.

    (1998)
  • D.W. Walker et al.

    Kynurenic acid in brain and cerebrospinal fluid of fetal, newborn, and adult sheep and effects of placental embolization

    Pediatr. Res.

    (1999)
  • J.B. Ubbink et al.

    High-performance liquid chromatographic assay of human lymphocyte kynureninase activity levels

    J. Chromatogr.

    (1991)
  • Cited by (34)

    • Tryptophan degradation enzymes and Angiotensin (1−7) expression in human placenta

      2022, Journal of Reproductive Immunology
      Citation Excerpt :

      The latest finding was interpreted by the authors as a compensatory effect to the significant reduction in IDO1 expression in pathological conditions. Conversely, a significant decrease of both TDO2 mRNA and protein expression was observed in the placentas of pregnancies complicated by fetal growth restriction (FGR) compared to controls (Murthi et al., 2017). One limitation of previous studies is that they evaluated TDO2 mRNA expression in the whole placenta, while in the present manuscript we have described the expression of TDO2 mRNA in the two distinct sides of the placenta, the maternal and the fetal surface.

    • Characterization of the temporal, cell-specific and interferon-inducible patterns of indoleamine 2,3 dioxygenase 1 (IDO1) expression in the human placenta across gestation

      2021, Placenta
      Citation Excerpt :

      Thus, one possible stimulus that may drive IDO1 expression is increased levels of oxygen in the placenta. A previous report stated that IDO1 mRNA and kynurenine levels were significantly elevated in placental explants cultured in vitro in 20% (i.e., atmospheric) versus 8% oxygen [31]. However, in vitro culture in 20% oxygen for 24 h did not increase IDO1 levels in villous explants from any gestational age relative to levels detected in villi processed immediately after dissection from the placenta (Fig. 2 versus 5; data not shown).

    View all citing articles on Scopus
    View full text